India mulls action against heads of WhatsApp, Facebook on failure to check fake news

Agencies
August 30, 2018

Abide by law or face prosecution -- this is the tough message likely to be sent to the India heads of social media platforms if the recommendations of a high-level government panel, which discussed steps to curb fake news and misinformation besides child pornography, are accepted.

The issue was discussed by a committee of secretaries, which was constituted following lynching of nearly 40 people in last one year suspectedly due to circulation of fake news in popular social media platforms like WhatsApp, an official privy to the development said.

The panel, headed by Union Home Secretary Rajiv Gauba, submitted its report to a Group of Ministers headed by Union Home Minister Rajnath Singh, which in turn will submit its recommendations to Prime Minister Narendra Modi.

"There are country representatives of all global social media platforms in India. Action may be initiated against them if they do not comply to remove objectionable contents and video from their sites," the official said. 

The top officials of different ministries and departments deliberated the issue in the wake of reports of many incidents of lynching, communal tension and abuse following circulation of fake news and communally sensitive contents and videos.

During recent meetings with the representatives of the Twitter India, Facebook, WhatsApp and Youtube, the government officials made it clear that the social media platforms have to comply with the directives without delay, and if not done, action under law would be initiated against them.

The law enforcement agencies have been maintaining that the social media platforms cannot remain aloof to the spread of "irresponsible and explosive messages" and they cannot evade their responsibilities.

Another official said that the India representatives of the social media platforms have promised to cooperate and the law enforcement agencies will closely monitor their actions.

The committee held consultations with a cross-section of society and other stakeholders before submitting its report to the GoM.

It is understood that they have suggested tightening the law by inserting clauses in the Indian Penal Code and the Code of Criminal Procedure through parliamentary approval.

The panel report will now be discussed by the GoM comprising External Affairs Minister Sushma Swaraj, Transport Minister Nitin Gadkari, Law Minister Ravi Shankar Prasad and Social Justice and Empowerment Minister Thawar Chand Gehlot. The home minister heads the GoM.

Last month, the Home Ministry issued advisories to states and Union Territories following the Supreme Court's directives to check incidents of lynching.

The Centre asked them to appoint an officer in each district at the level of Superintendent of Police, set up a special task force to gather intelligence, and closely monitor social media contents to prevent mob attacks on suspicion of being child-lifters or cattle smugglers.

In its communique to states and UTs, the ministry had said incidents of violence and lynching by mobs in some parts of the country fuelled by various kinds of rumours and unverified news such as child lifting, theft, cattle smuggling etc, are a matter of serious concerns.

Such instances of persons taking the law in their hands run against the basic tenets of the rule of law, it said.

"All state governments, UT administrations and their law enforcement agencies are requested to implement the directions of the Supreme Court in letter and spirit," it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 5,2020

New Delhi, Jun 5: Shares of Reliance Industries on Friday gained over 2 per cent to hit their one-year high level after the company announced sale of 1.85 per cent stake in its digital unit, Jio Platforms, to Abu Dhabi-based sovereign investor Mubadala.

On BSE, the heavyweight stock jumped 2.38 per cent to Rs 1,617.70 -- its 52-week high.

It surged 2.41 per cent to its one-year high of Rs 1,618 on NSE.

Earlier in the day, Reliance Industries announced the sale of 1.85 per cent stake in its digital unit to Mubadala for Rs 9,093.60 crore, the sixth deal in as many weeks that will inject a combined Rs 87,655.35 crore in the oil-to-telecom conglomerate to help it pare debt.

"Mubadala Investment Company (Mubadala) will invest Rs 9,093.60 crore in Jio Platforms at an equity value of Rs 4.91 lakh crore and an enterprise value of Rs 5.16 lakh crore," the company said in a statement.

With this investment, Jio Platforms has raised Rs 87,655.35 crore from leading global technology and growth investors including Facebook, Silver Lake, Vista Equity Partners, General Atlantic, KKR and Mubadala in less than six weeks.

Jio Platforms, a wholly-owned subsidiary of Reliance Industries Ltd, is a next-generation technology company.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 14,2020

New Delhi, May 14: With a spike of 3,722 new cases in the last 24 hours, the COVID-19 count in India reached 78,003 on Thursday morning, according to the Ministry of Health and Family Welfare.

As per the latest update by the Ministry, there are 49,219 active cases in the country while 26,235 patients have been cured and discharged, and one migrated, so far.

With 134 new deaths being reported due to the disease since yesterday, the toll due to the disease reached 2,549.

With 25,922 confirmed cases, Maharashtra is the worst affected by the infection in the country so far.

Gujarat and Tamil Nadu, with 9,267 and 9,227, cases respectively are the next worst affected by the disease.

The national capital, Delhi, is just a couple of cases behind the 8 thousand mark as per the update on Thursday morning.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.